Floatz logo

Gimatecan

Brain and Central Nervous System Tumors

Jonsson Comprehensive Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

48 Active assets in the Brain and Central Nervous System Tumors cohort.

Asset / SponsorPhaseRating
Procarbazine
Universitätsmedizin Mannheim
Phase 3BBB
VINCRISTINE SULFATE
Northwestern University
Phase 3BBB
Irinotecan
EpicentRx, Inc.
Phase 2BBB
ETOPOSIDE
NewLink Genetics Corporation
Phase 3BBB
Gefetinib
Memorial Sloan Kettering Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Gimatecan is also rated in:

ovarian carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
peritoneum cancerDormant
CCC
Indicative ·
53 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →